Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ark Bio of Shanghai Starts Phase II Trial of Novel RSV Treatment

publication date: Aug 17, 2016
Ark Biosciences, a Shanghai biopharma located in Zhangjiang Hi-Tec Park, has begun dosing patients in a global Phase II trial of AK0529, a novel treatment for respiratory syncytial virus (RSV). RSV is a common infection among infants, and although usually not serious, it is the leading cause of hospitalization in infants under the age of one. Ark in-licensed global rights to ARK0529 from Roche two years ago. In its Phase I trial, conducted in Australia, ARK0529 was well tolerated with predictable pharmacokinetics. More details....

Stock Symbol: (SX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital